Pharmaceutical Companies in Iran
A comprehensive guide to the pharmaceutical industry in Iran — the MENA region's second-largest pharma market by volume. Covering major pharma companies, IFDA regulatory framework, 95% local production, market data, distribution channels, and strategic opportunities.
Last updated: February 2026 · Sources: IFDA, industry reports, company filings
Cite this guide
BioNixus. "Pharmaceutical Companies in Iran: Complete Industry Guide 2026." BioNixus Healthcare Market Research, Feb. 2026, https://www.bionixus.com/pharmaceutical-companies-iran.
Licensed under CC BY 4.0 — free to share and adapt with attribution.
$4.2B
Pharmaceutical market value
7.3%
Year-over-year growth
88.6M
Population
$47
Pharma spending per capita
Iran Pharmaceutical Market Overview
Iran is the MENA region's second-largest pharmaceutical market by volume, valued at approximately US$4.2 billion, growing at 7.3% year-over-year. With a population of 88.6 million (the largest in the region) and per-capita pharmaceutical spending of $47, Iran is uniquely 95% self-sufficient in pharmaceutical production — about 180+ manufacturers supply the vast majority of medicines domestically.
Sanctions have driven local innovation, especially in biosimilars (insulin, EPO) and generics. Only around 5% of the market is supplied by imports. The Iran Food and Drug Administration (IFDA) regulates all aspects of registration, pricing (government-controlled), and distribution. For broader regional context, see our MENA Pharmaceutical Market Data 2026 and GCC Pharmaceutical Market Access Guide.
Top Pharmaceutical Companies in Iran
The following table lists major pharmaceutical companies operating in Iran — including local manufacturers, limited MNC presence, regional suppliers, and leading distributors.
| Company | HQ |
|---|---|
| Darou Pakhsh | Iran |
| Sobhan Pharmaceutical | Iran |
| Razak Laboratories | Iran |
| Abidi Pharmaceutical | Iran |
| Hakim Pharmaceutical | Iran |
| Exir Pharmaceutical | Iran |
| Osvah Pharmaceutical | Iran |
| Rouz Darou | Iran |
| Cinnagen | Iran |
| Tehran Chemie | Iran |
| Novartis | Switzerland |
| Roche | Switzerland |
| Sanofi | France |
| Cipla | India |
| Dr. Reddy's | India |
| Ranbaxy / Sun Pharma | India |
| Darou Pakhsh Distribution | Iran |
| Hakim Distribution | Iran |
| TPICO (Tehran Pharma Investment Co.) | Iran |
List of Pharmaceutical Companies in Iran by Category
Iran pharmaceutical companies span dominant local manufacturers (95% of supply), limited MNC operations through distributors or partners, regional Indian suppliers, and major distributors controlling the IFDA-regulated chain.
Local Manufacturers
Iran has 180+ licensed pharmaceutical manufacturers; approximately 95% of medicines are produced locally. Leaders include Darou Pakhsh (10% market share), Sobhan (biologics, insulin), Razak (generics, exports), Cinnagen (biotech, EPO, insulin), and Exir (biosimilars, vaccines).
- ✓ Darou Pakhsh
- ✓ Sobhan Pharmaceutical
- ✓ Razak Laboratories
- ✓ Abidi Pharmaceutical
- ✓ Hakim Pharmaceutical
- ✓ Exir Pharmaceutical
- ✓ Osvah Pharmaceutical
- ✓ Rouz Darou
- ✓ Cinnagen
- ✓ Tehran Chemie
MNC Offices (Limited)
Multinational presence is limited due to sanctions. Novartis, Roche, and Sanofi operate through limited operations, distributors, or local partners. Post-sanctions scenarios could expand MNC engagement.
- ✓ Novartis
- ✓ Roche
- ✓ Sanofi
Regional (India)
Indian companies such as Cipla, Dr. Reddy's, and Ranbaxy/Sun Pharma supply generics to Iran, with growing export volumes.
- ✓ Cipla
- ✓ Dr. Reddy's
- ✓ Ranbaxy / Sun Pharma
Distributors
Distribution is dominated by Darou Pakhsh Distribution (largest), Hakim Distribution, and TPICO. IFDA controls the distribution chain; 10,000+ pharmacies operate nationwide.
- ✓ Darou Pakhsh Distribution
- ✓ Hakim Distribution
- ✓ TPICO (Tehran Pharma Investment Co.)
Pharma Companies in Iran: IFDA Regulatory Landscape
The Iran Food and Drug Administration (IFDA) regulates pharmaceutical registration, quality control, government-controlled pricing, and the distribution chain.
Regulatory Authority
The Iran Food and Drug Administration (IFDA) oversees all pharmaceutical registration, quality control, pricing (government-controlled), pharmacovigilance, and distribution. IFDA controls the entire supply chain from registration to pharmacy.
Registration Timeline
12–24 months
Renewal Period
5 years
Pricing Model
Government-controlled pricing (IFDA)
Key Registration Requirements
- ✓Full dossier submission to IFDA
- ✓GMP certificates and stability data
- ✓Labelling in Persian (Farsi)
- ✓Local representative typically required for foreign manufacturers
- Government-controlled pricing set by IFDA
Drug Distribution Channels in Iran
Iran's pharmaceutical distribution is government-dominated, with insurance bodies and IFDA controlling the chain. Over 10,000 pharmacies operate nationwide.
Government & Insurance (~95% coverage)
The Social Security Organization, Armed Forces insurance, and Salamat insurance cover approximately 95% of the population. IFDA controls the distribution chain from manufacturer to pharmacy.
- ► Social Security Organization (major payer)
- ► Armed Forces and Salamat insurance
- ► 10,000+ pharmacies nationwide
- ► IFDA-regulated supply chain
Key Distributors
Darou Pakhsh Distribution is the largest pharma distributor; Hakim Distribution and TPICO (Tehran Pharma Investment Co.) are other major players. All operate under IFDA oversight.
- ► Darou Pakhsh Distribution
- ► Hakim Distribution, TPICO
Iran Pharmaceutical Market Growth Drivers
Self-sufficiency, population size, and innovation under constraints drive Iran's pharmaceutical sector.
95% Local Production
Iran is one of the most self-sufficient pharma markets globally. Approximately 95% of medicines are produced domestically by 180+ manufacturers, with only ~5% import dependency. This creates a resilient supply base and export potential.
88.6M Population
Iran has the largest population in the region (88.6 million), providing a large addressable market and sustained demand for generics, biosimilars, and essential medicines.
Biosimilar Development Hub
Sanctions have accelerated local R&D in biosimilars (insulin, EPO) and vaccines. Companies like Sobhan, Cinnagen, and Exir are regional leaders in biotech and biosimilars.
Knowledge-Based Economy Push
Government emphasis on knowledge-based enterprises and university–pharma research partnerships supports innovation and local drug development.
University–Pharma Partnerships
Strong linkages between universities and pharmaceutical companies drive R&D, clinical trials, and talent pipeline for the domestic industry.
Post-Sanctions Opportunity
Any easing of sanctions could open significant opportunities for foreign investment, MNC partnerships, technology transfer, and export growth.
How BioNixus Supports Pharma Companies in Iran
BioNixus provides healthcare market research and strategic support for companies engaging with the Iranian pharmaceutical market. We help with:
Market & Competitive Intelligence
Assessment of local manufacturers, biosimilar capabilities, distribution landscape, and competitive dynamics in Iran's pharma sector.
IFDA & Market Access Strategy
Regulatory pathway analysis, IFDA registration process, government pricing and reimbursement landscape, and partner identification.
Partner & Distributor Mapping
Identification of credible local partners, distributors (e.g. Darou Pakhsh Distribution, TPICO), and potential collaboration opportunities.
Post-Sanctions Readiness
Scenario planning, market entry strategies, and commercial due diligence for companies considering Iran once regulatory and trade conditions allow.
Frequently Asked Questions
How many pharmaceutical companies operate in Iran?
Iran has over 180 licensed pharmaceutical manufacturers and hundreds of registered companies including multinational offices (limited due to sanctions), regional suppliers, and distributors. The market is the second-largest in MENA by volume, valued at $4.2 billion, with approximately 95% of pharmaceuticals produced locally.
What is the size of Iran's pharmaceutical market?
Iran's pharmaceutical market is valued at approximately US$4.2 billion, growing at 7.3% year-over-year. With a population of 88.6 million (the largest in the region) and per-capita pharmaceutical spending of $47, Iran is uniquely self-sufficient — about 95% of drugs consumed are produced domestically.
How dominant is local pharmaceutical manufacturing in Iran?
Iran is one of the most self-sufficient pharmaceutical markets globally: approximately 95% of medicines are produced locally by 180+ manufacturers. Sanctions have driven local innovation, especially in biosimilars (insulin, EPO) and generics. Only around 5% of the market is supplied by imports.
How do sanctions affect the pharmaceutical market in Iran?
Sanctions have limited direct MNC operations; many global companies (e.g. Novartis, Roche, Sanofi) operate through distributors or local partners. They have also accelerated local R&D and biosimilar development. Post-sanctions scenarios could open significant opportunities for foreign investment and partnerships.
Does Iran have biosimilar capabilities?
Yes. Iran has developed a strong biosimilar sector driven by necessity under sanctions. Companies such as Sobhan Pharmaceutical (insulin), Cinnagen (EPO, insulin), and Exir Pharmaceutical (biosimilars, vaccines) are regional leaders. University–pharma research partnerships and a knowledge-based economy push support ongoing development.
How do you register a pharmaceutical product with IFDA?
Drug registration with the Iran Food and Drug Administration (IFDA) requires submission of a full dossier including GMP certificates, stability data, and labelling in Persian. The process typically takes 12–24 months. IFDA controls pricing (government-controlled), distribution chain, and renewal (5-year renewal). A local representative is typically required for foreign manufacturers.
Data Sources & Methodology
This guide aggregates publicly available information from:
- IFDA and Iranian pharmaceutical industry sources
- Industry reports and company filings
- BioNixus proprietary research and market assessments
For customised market intelligence on Iran, contact our team.
Need Market Intelligence on Iran?
BioNixus delivers custom pharmaceutical market research and strategy support for Iran — competitive intelligence, IFDA regulatory guidance, partner mapping, and post-sanctions readiness.